MBX Biosciences, Inc. (NASDAQ:MBX) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on MBX Biosciences, with 10 buy ratings, one strong-buy rating and two sell ratings. The average 12-month price target is $77, with recent targets ranging from $56 to $88.
• MBX shares opened at $66.33, near their 52-week high of $72.64, and have risen above their longer-term moving averages. The company has a market capitalization of approximately $3.19 billion.
• The clinical-stage biotech reported quarterly adjusted EPS of -$0.78, missing the consensus estimate of -$0.68; analysts expect a full-year loss of about $3.12 per share.

MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the thirteen ratings firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $77.00.

Several brokerages have issued reports on MBX. Stifel Nicolaus set a $56.00 price objective on MBX Biosciences in a research report on Tuesday, May 12th. JPMorgan Chase & Co. assumed coverage on MBX Biosciences in a report on Friday. They set an "overweight" rating and a $88.00 target price on the stock. Wall Street Zen lowered MBX Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of MBX Biosciences in a report on Friday, July 17th. Finally, Truist Financial lifted their price target on MBX Biosciences from $70.00 to $88.00 and gave the company a "buy" rating in a report on Monday, August 10th.

MBX Biosciences Stock Down 0.0%

NASDAQ:MBX opened at $66.33 on Friday. The firm has a market cap of $3.19 billion, a PE ratio of -27.52 and a beta of 0.10. MBX Biosciences has a 12 month low of $9.63 and a 12 month high of $72.64. The company's 50-day moving average price is $59.31 and its two-hundred day moving average price is $42.01.

MBX Biosciences (NASDAQ:MBX - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.10). On average, research analysts expect that MBX Biosciences will post -3.12 EPS for the current fiscal year.

Hedge Funds Weigh In On MBX Biosciences

A number of institutional investors have recently modified their holdings of the stock. State of Wyoming acquired a new position in shares of MBX Biosciences during the second quarter worth approximately $58,000. Russell Investments Group Ltd. increased its holdings in shares of MBX Biosciences by 4,131.4% in the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company's stock valued at $26,000 after purchasing an additional 1,446 shares in the last quarter. Royal Bank of Canada raised its position in MBX Biosciences by 59.6% in the 4th quarter. Royal Bank of Canada now owns 1,532 shares of the company's stock worth $49,000 after purchasing an additional 572 shares during the last quarter. Strs Ohio lifted its holdings in MBX Biosciences by 128.6% during the 1st quarter. Strs Ohio now owns 1,600 shares of the company's stock worth $48,000 after buying an additional 900 shares in the last quarter. Finally, California State Teachers Retirement System lifted its holdings in MBX Biosciences by 64.7% during the 4th quarter. California State Teachers Retirement System now owns 1,754 shares of the company's stock worth $55,000 after buying an additional 689 shares in the last quarter.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source